Novavax, Inc. Stock price Nasdaq
Equities
US6700021040
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 852M | Sales 2025 * | 952M | Capitalization | 719M |
---|---|---|---|---|---|
Net income 2024 * | -103M | Net income 2025 * | 35M | EV / Sales 2024 * | 0.35 x |
Net cash position 2024 * | 422M | Net cash position 2025 * | 297M | EV / Sales 2025 * | 0.44 x |
P/E ratio 2024 * |
-5.64
x | P/E ratio 2025 * |
28.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.38% |
Latest transcript on Novavax, Inc.
Managers | Title | Age | Since |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
1st Jan change | Capi. | |
---|---|---|
+9.72% | 46.21B | |
+35.14% | 40.04B | |
+4.84% | 39.92B | |
-9.43% | 28.33B | |
+17.47% | 27.43B | |
-22.99% | 18.57B | |
+10.88% | 13.46B | |
+27.53% | 12.02B | |
-6.84% | 11.3B |